Catherine Copigneaux

529 total citations
17 papers, 419 citations indexed

About

Catherine Copigneaux is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Catherine Copigneaux has authored 17 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Catherine Copigneaux's work include HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Catherine Copigneaux is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Catherine Copigneaux collaborates with scholars based in United States, Germany and Japan. Catherine Copigneaux's co-authors include Robert A. Beckman, Tina E. Wood, Feng Luo, Jatin J. Shah, Mansoor N. Saleh, Andres Forero‐Torres, Slawomir Wojtowicz‐Praga, James Posey, Ivor Percent and Abdel‐Baset Halim and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Catherine Copigneaux

17 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine Copigneaux United States 9 259 206 119 109 78 17 419
YounJeong Choi United States 11 206 0.8× 135 0.7× 75 0.6× 106 1.0× 46 0.6× 17 369
Andrew Elliott United States 10 260 1.0× 191 0.9× 65 0.5× 146 1.3× 54 0.7× 99 483
Véronique Cabaret France 9 392 1.5× 158 0.8× 229 1.9× 90 0.8× 149 1.9× 20 588
Rodrigo Ruiz-Soto United States 9 186 0.7× 174 0.8× 66 0.6× 90 0.8× 32 0.4× 19 408
Fernando Ortiz-Martínez Spain 9 220 0.8× 221 1.1× 78 0.7× 77 0.7× 17 0.2× 12 419
Felix Meyer Germany 10 289 1.1× 341 1.7× 46 0.4× 117 1.1× 45 0.6× 20 646
Greg Friberg United States 10 189 0.7× 259 1.3× 50 0.4× 116 1.1× 64 0.8× 15 488
Catherine J. Kennedy Australia 13 194 0.7× 234 1.1× 44 0.4× 176 1.6× 26 0.3× 25 560
Carla Castanaro United States 6 159 0.6× 245 1.2× 31 0.3× 73 0.7× 102 1.3× 9 434
Caipeng Qin China 12 85 0.3× 202 1.0× 51 0.4× 93 0.9× 79 1.0× 41 359

Countries citing papers authored by Catherine Copigneaux

Since Specialization
Citations

This map shows the geographic impact of Catherine Copigneaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Copigneaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Copigneaux more than expected).

Fields of papers citing papers by Catherine Copigneaux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Copigneaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Copigneaux. The network helps show where Catherine Copigneaux may publish in the future.

Co-authorship network of co-authors of Catherine Copigneaux

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Copigneaux. A scholar is included among the top collaborators of Catherine Copigneaux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Copigneaux. Catherine Copigneaux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Oaknin, Ana, Kathleen N. Moore, Tim Meyer, et al.. (2024). Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial. The Lancet Oncology. 25(5). 588–602. 32 indexed citations
2.
Forero, Andres, Johanna C. Bendell, Prasanna Kumar, et al.. (2017). First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Investigational New Drugs. 35(3). 298–306. 30 indexed citations
3.
Yonesaka, Kimio, Kenji Hirotani, Joachim von Pawel, et al.. (2017). Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. Lung Cancer. 105. 1–6. 19 indexed citations
4.
Serwatowski, Piotr, Aleksandra Szczęsna, Joachim von Pawel, et al.. (2017). P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study. Journal of Thoracic Oncology. 12(1). S1214–S1215. 9 indexed citations
5.
Yonesaka, Kimio, Kenji Hirotani, Joachim von Pawel, et al.. (2016). Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer.. Journal of Clinical Oncology. 34(15_suppl). 9071–9071. 4 indexed citations
6.
7.
Pawel, Joachim von, Jeng‐Sen Tseng, Mircea Dediu, et al.. (2015). Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs). Pneumologie. 69(S 01). 3 indexed citations
8.
Marshall, John L., Dale E. Shuster, Terri Goldberg, et al.. (2014). A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 32(3_suppl). 535–535. 4 indexed citations
9.
Paz‐Ares, Luis, Joachim von Pawel, Berta Moritz, et al.. (2014). Phase (Ph) 3 Study of Patritumab (P) Plus Erlotinib (E) in Egfr Wild-Type Subjects with Advanced Non–Small Cell Lung Cancer (Nsclc). Annals of Oncology. 25. iv470–iv470. 4 indexed citations
10.
Mendell‐Harary, Jeanne, Jens E. Ruhe, Matthias Schneider, et al.. (2014). Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC.. Journal of Clinical Oncology. 32(15_suppl). e19016–e19016. 1 indexed citations
11.
Pawel, Joachim von, Jennifer Tseng, Mircea Dediu, et al.. (2014). Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).. Journal of Clinical Oncology. 32(15_suppl). 8045–8045. 19 indexed citations
12.
LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations
13.
14.
Pishvaian, Michael J., John L. Marshall, Andrew J. Wagner, et al.. (2012). A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 118(21). 5403–5413. 60 indexed citations
15.
Keedy, Vicki L., Pasi A. Jänne, Lorrin Yee, et al.. (2011). A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3026–3026. 7 indexed citations
16.
Forero‐Torres, Andres, Jatin J. Shah, Tina E. Wood, et al.. (2010). Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5). Cancer Biotherapy and Radiopharmaceuticals. 25(1). 13–19. 116 indexed citations
17.
Pishvaian, Michael J., Ion Cotarla, Amy J. Wagner, et al.. (2010). Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.. Journal of Clinical Oncology. 28(15_suppl). 2526–2526. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by YounJeong Choi Breakdown of academic impact, for papers by Andrew Elliott Breakdown of academic impact, for papers by Véronique Cabaret Breakdown of academic impact, for papers by Rodrigo Ruiz-Soto Breakdown of academic impact, for papers by Fernando Ortiz-Martínez Breakdown of academic impact, for papers by Felix Meyer Breakdown of academic impact, for papers by Greg Friberg Breakdown of academic impact, for papers by Catherine J. Kennedy Breakdown of academic impact, for papers by Carla Castanaro Breakdown of academic impact, for papers by Caipeng Qin
Rankless by CCL
2026